261 related articles for article (PubMed ID: 22140466)
1. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
Mielcarek M; Benn CL; Franklin SA; Smith DL; Woodman B; Marks PA; Bates GP
PLoS One; 2011; 6(11):e27746. PubMed ID: 22140466
[TBL] [Abstract][Full Text] [Related]
2. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.
Benn CL; Butler R; Mariner L; Nixon J; Moffitt H; Mielcarek M; Woodman B; Bates GP
PLoS One; 2009 Jun; 4(6):e5747. PubMed ID: 19484127
[TBL] [Abstract][Full Text] [Related]
3. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.
Moumné L; Campbell K; Howland D; Ouyang Y; Bates GP
PLoS One; 2012; 7(2):e31080. PubMed ID: 22347433
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
Hockly E; Richon VM; Woodman B; Smith DL; Zhou X; Rosa E; Sathasivam K; Ghazi-Noori S; Mahal A; Lowden PA; Steffan JS; Marsh JL; Thompson LM; Lewis CM; Marks PA; Bates GP
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2041-6. PubMed ID: 12576549
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
6. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
Bobrowska A; Paganetti P; Matthias P; Bates GP
PLoS One; 2011; 6(6):e20696. PubMed ID: 21677773
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
Koppel I; Timmusk T
Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
[TBL] [Abstract][Full Text] [Related]
8. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo.
Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR
Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
Sharma S; Taliyan R
Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of BDNF Expression and Memory by HDAC Inhibition Requires BET Bromodomain Reader Proteins.
Sartor GC; Malvezzi AM; Kumar A; Andrade NS; Wiedner HJ; Vilca SJ; Janczura KJ; Bagheri A; Al-Ali H; Powell SK; Brown PT; Volmar CH; Foster TC; Zeier Z; Wahlestedt C
J Neurosci; 2019 Jan; 39(4):612-626. PubMed ID: 30504275
[TBL] [Abstract][Full Text] [Related]
12. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.
Zhu Z; Jiang W; McGinley JN; Thompson HJ
Cancer Prev Res (Phila); 2013 Apr; 6(4):290-8. PubMed ID: 23365133
[TBL] [Abstract][Full Text] [Related]
13. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
14. Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.
Ragot A; Pietropaolo S; Vincent J; Delage P; Zhang H; Allinquant B; Leinekugel X; Fischer A; Cho YH
Brain Behav; 2015 Sep; 5(9):e00361. PubMed ID: 26445700
[TBL] [Abstract][Full Text] [Related]
15. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
16. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
17. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Dompierre JP; Godin JD; Charrin BC; Cordelières FP; King SJ; Humbert S; Saudou F
J Neurosci; 2007 Mar; 27(13):3571-83. PubMed ID: 17392473
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
20. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C
Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
